Amgen (AMGN) Ceases Ganitumab Phase 3 GAMMA; DMC Says Statistically Significant Improvement Unlikely

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/19/2026

1. KEYS
2. MRNA
3. KLAR
4. PANW
5. HD
6. DVLT
7. MRK
8. PGR
9. EPM
10. MRCY

Go back to Amgen (AMGN) Ceases Ganitumab Phase 3 GAMMA; DMC Says Statistically Significant Improvement Unlikely
Amgen Inc (NASDAQ: AMGN) Delayed: 438.45 +13.17 (3.10%)
Previous Close $425.28    52 Week High $176.85 
Open $430.24    52 Week Low $133.64 
Day High $441.98    P/E 66.03 
Day Low $429.38    EPS $6.64 
Volume 1,251,269